Capzer Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Capzer Pharmaceuticals is a private, revenue-generating CDMO focused on small molecule and oncology sectors, though its primary business is contract services for a broad range of pharmaceutical and nutraceutical products. The company emphasizes its integrated 'one-stop' model for development, manufacturing, and packaging, supported by FDA and DEA registration. With plans for facility expansion and international joint ventures, Capzer aims to grow its presence in the US and enter new markets in Asia, the Caribbean, and South America.

Oncology

Technology Platform

Integrated CDMO service platform offering co-located R&D, cGMP manufacturing (oral solids, liquids, injectables), and packaging for pharmaceuticals and nutraceuticals. FDA & DEA registered.

Opportunities

Expansion of its Florida GMP facility can increase capacity and attract larger clients.

Forming joint ventures to enter Asian, Caribbean, and South American markets presents a significant geographic growth opportunity in regions with rising demand for pharmaceutical manufacturing.

Risk Factors

Revenue is entirely dependent on third-party client projects, creating vulnerability to biotech funding cycles and client attrition.

Regulatory compliance risk is high, as any FDA enforcement action could halt operations.

Execution risk surrounds its physical and international expansion plans.

Competitive Landscape

Operates in the highly competitive CDMO market, competing against large global players (e.g., Lonza, Catalent) and many smaller niche providers. Differentiation is based on integrated US-based services, regulatory compliance, and targeted expertise in small molecules and oncology formulations.

More companies in Small Molecule Drugs →More companies in United States →